PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-72.53%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-106.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-634.78%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-634.78%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1141.09%
Negative net income growth while VET stands at 94.59%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-1141.36%
Negative EPS growth while VET is at 94.66%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1141.36%
Negative diluted EPS growth while VET is at 94.66%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.17%
Maintaining or increasing dividends while VET cut them. John Neff might see a strong edge in shareholder returns.
-79.33%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
39.73%
Positive FCF growth while VET is negative. John Neff would see a strong competitive edge in net cash generation.
-71.94%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-43.36%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-49.79%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-92.56%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-74.58%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-59.80%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-392.82%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-76.29%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1091.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-80.13%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-51.35%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-35.15%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-90.34%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-56.24%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
33.76%
Our short-term dividend growth is positive while VET cut theirs. John Neff views it as a comparative advantage in shareholder returns.
-9.41%
Firm’s AR is declining while VET shows 23.69%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-42.37%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
4.38%
Debt growth far above VET's 6.49%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
18.71%
We expand SG&A while VET cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.